Trial reportBMC cancer2012
Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
Trial report in BMC cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 115 citations in OpenAlex.
- Effects of Daily Raspberry Consumption on Immune-Metabolic Health in Subjects at Risk of Metabolic Syndrome: A Randomized Controlled Trial.Nutrients · 2020Trial
- Article
- Applications of Metabolomics to the Clinical Management of Breast Cancer: New Perspectives for Diagnosis, Treatment and Prognosis.International journal of molecular sciences · 2026Review
- Resistance to neoadjuvant chemotherapy in breast cancers: a metabolic perspective.Journal of experimental & clinical cancer research : CR · 2025Review
- Comprehensive MALDI mass spectrometry imaging of tumor regions post-neoadjuvant therapy.Analytical and bioanalytical chemistry · 2025Article
- Detecting Glutathione and Related Antioxidants as Biomarkers in Patient Breast Tumor Tissues: An Update in the Age of Metabolomics.Oxidative medicine and cellular longevity · 2025Review
- Transmembrane Amino Acid Transporters in Shaping the Metabolic Profile of Breast Cancer Cell Lines: The Focus on Molecular Biological Subtype.Current issues in molecular biology · 2024Review
- Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics.Breast cancer research and treatment · 2024Article
- Metabolomic Profiling of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy for Predicting Disease-Free and Overall Survival.International journal of molecular sciences · 2024Article
- EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis.Breast cancer research : BCR · 2024Article
- Metabolomic profiles of intact tissues reflect clinically relevant prostate cancer subtypes.Journal of translational medicine · 2023Article
- DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.Breast cancer research : BCR · 2022Article
- Article
- Seasonal variation in serum metabolites of northern European dogs.Journal of veterinary internal medicine · 2022Article
- Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer.Frontiers in oncology · 2022Article
- Reduction of Rapid Proliferating Tumour Cell Lines by Inhibition of the Specific Glycine Transporter GLYT1.Biomedicines · 2021Article
- Impact of the PdInternational journal of molecular sciences · 2021Article
- Review
- An 8-week freeze-dried blueberry supplement impacts immune-related pathways: a randomized, double-blind placebo-controlled trial.Genes & nutrition · 2021Article
- Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundToday's clinical diagnostic tools are insufficient for giving accurate prognosis to breast cancer patients. The aim of our study was to examine the tumor metabolic changes in patients with locally advanced breast cancer caused by neoadjuvant chemotherapy (NAC), relating these changes to clinical treatment response and long-term survival.
methodsPatients (n = 89) participating in a randomized open-label multicenter study were allocated to receive either NAC as epirubicin or paclitaxel monotherapy. Biopsies were excised pre- and post-treatment, and analyzed by high resolution magic angle spinning magnetic resonance spectroscopy (HR MAS MRS). The metabolite profiles were examined by paired and unpaired multivariate methods and findings of important metabolites were confirmed by spectral integration of the metabolite peaks.
resultsAll patients had a significant metabolic response to NAC, and pre- and post-treatment spectra could be discriminated with 87.9%/68.9% classification accuracy by paired/unpaired partial least squares discriminant analysis (PLS-DA) (p < 0.001). Similar metabolic responses were observed for the two chemotherapeutic agents. The metabolic responses were related to patient outcome. Non-survivors (< 5 years) had increased tumor levels of lactate (p = 0.004) after treatment, while survivors (≥ 5 years) experienced a decrease in the levels of glycine (p = 0.047) and choline-containing compounds (p ≤ 0.013) and an increase in glucose (p = 0.002) levels. The metabolic responses were not related to clinical treatment response.
conclusionsThe differences in tumor metabolic response to NAC were associated with breast cancer survival, but not to clinical response. Monitoring metabolic responses to NAC by HR MAS MRS may provide information about tumor biology related to individual prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.